Nobody dares to stop clinical research, not even COVID-19
In the global health emergency caused by the SARS-CoV-2 virus, clinical trial management has proven critical for the pharmaceutical industry and healthcare professionals. This article discussed the importance of adopting measures which, primarily, prioritize patient safety and data validity, as well as the use of contingency measures such as telemedicine, virtual medical examination and remote monitoring. All with the goal of ensuring that clinical cancer research continues during the SARS-CoV-2 pandemic.
DOI: 10.1038/s41523-021-00249-1